Purchase this article with an account.
G. M. Haffner, N. A. Chaudhry, D. Tom, N. Miller-Rivero, J. M. Colina-Luquez, P. E. Liggett; Bevacizumab Efficacy in Chronic Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):286.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the use of intravitreal bevacizumab in patients with persistent chronic central serous chorioretinopathy (CSCR)
Four eyes of 3 patents were included in the study. All eyes had chronic CSCR and persistent subretinal fluid refractory to standard therapy of macular laser and photodynamic therapy. All patients underwent flourescein angiography demonstrating diffuse RPE mottling and active leakage. Optical coherence tomography demonstrated persistent subretinal fluid. All eyes recieved a single intravitreal injection of bevacizumab (1.25 mg.
: Post injection follow-up ranged from 2 to 7 months (average 5 months). Snellen visual acuity improved in 1 patient from 20/80 to 20/25 while vision remained unchanged in the remaining 3 eyes (20/40, 20/80, and 20/200). Three out of 4 eyes showed complete resolution of the subretinal fluid.while the fourth eye showed persistent subretinal fluid with unchanged visual acuity of 20/200.
Intravitreal bevacizumab may have some effect in refractory CSCR cases in improving visual acuity and augmenting subretinal fluid resolution. However visual improvement appears to be less satisfactory and may be related to the chronic nature of the disease.
This PDF is available to Subscribers Only